Individuals who carry pathogenic BRCA variants are often identified only after a cancer diagnosis because about half of these persons lack relevant family history (FH),1 and BRCA screening is not routinely performed. Unaffected carriers of pathogenic variants unaware of their genetic status cannot undertake recommended surveillance and prevention measures, including risk-reduction bilateral mastectomy (RRBM), which reduces breast cancer risk in carriers of pathogenic BRCA variants2 and overall mortality in BRCA1 carriers.3 However, worldwide, most carriers decline RRBM.4 We hypothesized that among carriers who decline RRBM and ultimately develop breast cancer, knowing their BRCA status before cancer diagnosis might lead to breast cancer downstaging at diagnosis and measurable downstream benefits.
Identify all potential conflicts of interest that might be relevant to your comment.
Conflicts of interest comprise financial interests, activities, and relationships within the past 3 years including but not limited to employment, affiliation, grants or funding, consultancies, honoraria or payment, speaker's bureaus, stock ownership or options, expert testimony, royalties, donation of medical equipment, or patents planned, pending, or issued.
Err on the side of full disclosure.
If you have no conflicts of interest, check "No potential conflicts of interest" in the box below. The information will be posted with your response.
Not all submitted comments are published. Please see our commenting policy for details.
Hadar T, Mor P, Amit G, et al. Presymptomatic Awareness of Germline Pathogenic BRCA Variants and Associated Outcomes in Women With Breast Cancer. JAMA Oncol. 2020;6(9):1460–1463. doi:10.1001/jamaoncol.2020.2059
Customize your JAMA Network experience by selecting one or more topics from the list below.
Create a personal account or sign in to: